NCT06755671 A Prospective Multicentre Real-world Assessment of the Efficacy of Danning Tablets in Alleviating Digestive Symptoms
| NCT ID | NCT06755671 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Shanghai Hutchison Pharmaceuticals Limited |
| Condition | Indigestion |
| Study Type | OBSERVATIONAL |
| Enrollment | 4,500 participants |
| Start Date | 2025-04-30 |
| Primary Completion | 2027-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 4,500 participants in total. It began in 2025-04-30 with a primary completion date of 2027-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this observational study is to evaluate if Danning Tablets are effective in alleviating dyspepsia in patients with any of the following digestive symptoms: upper abdominal pain, bloating, loss of appetite, acid reflux or constipation. The main questions it aims to answer are: How effective are Danning Tablets for patients with indigestion symptoms? What are the impact factors (e.g. severity of conditions, demographic features, dose and length of treatment etc.) of the efficacy of Danning Tablets for indigestion patients? Participants already taking Danning Tablets as part of their regular medical care for indigestion will take questionnaires by the end of two weeks and four weeks respectively from the start of their treatment.
Eligibility Criteria
Inclusion Criteria: * Patients between 18 and 75 years old * Patients with at least one of the following symptoms: upper abdominal pain, bloating, loss of appetite, acid reflux or constipation * Patients already taking Danning Tablets as part of their regular medicine treatment for dyspepsia * Patients agree to sign the informed consent form Exclusion Criteria: * Past history or comorbidity of malignant tumor * Comorbidity of severe systemic condition including cardiovascular, cerebrovascular, renal and hematopoietic system diseases * Past history of abdominal surgery (post pancreatic surgery, post subtotal gastrectomy; incomplete intestinal obstruction) or mental illness, mobility difficulty (e.g. long-term bed ridden) * Comorbidity of any unstable chronic or acute disease,which may impact the evaluation of treatment efficacy as determined by the research physician * Pregnancy or breastfeeding * Participation in other clinical trials within the past 3 months * Other circumstances determined as ineligible by the research physician
Contact & Investigator
Jianting CAI, Doctor of Medicine
PRINCIPAL INVESTIGATOR
Second Affiliated Hospital, Zhejiang University, School of Medicine
Frequently Asked Questions
Who can join the NCT06755671 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Indigestion. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06755671 currently recruiting?
Yes, NCT06755671 is actively recruiting participants. Contact the research team at gaoyichen@shpl.com.cn for enrollment information.
Where is the NCT06755671 trial being conducted?
This trial is being conducted at Hangzhou, China.
Who is sponsoring the NCT06755671 clinical trial?
NCT06755671 is sponsored by Shanghai Hutchison Pharmaceuticals Limited. The principal investigator is Jianting CAI, Doctor of Medicine at Second Affiliated Hospital, Zhejiang University, School of Medicine. The trial plans to enroll 4,500 participants.